vs
Side-by-side financial comparison of PETMED EXPRESS INC (PETS) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
PETMED EXPRESS INC is the larger business by last-quarter revenue ($40.7M vs $20.4M, roughly 2.0× Sight Sciences, Inc.). Sight Sciences, Inc. runs the higher net margin — -20.4% vs -26.0%, a 5.5% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -23.3%). Sight Sciences, Inc. produced more free cash flow last quarter ($-2.0M vs $-9.2M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -20.9%).
PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
PETS vs SGHT — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.7M | $20.4M |
| Net Profit | $-10.6M | $-4.2M |
| Gross Margin | 23.3% | 87.3% |
| Operating Margin | -25.7% | -18.0% |
| Net Margin | -26.0% | -20.4% |
| Revenue YoY | -23.3% | 6.9% |
| Net Profit YoY | -1392.6% | 64.9% |
| EPS (diluted) | $-0.50 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $40.7M | $20.4M | ||
| Q3 25 | $44.4M | $19.9M | ||
| Q2 25 | $51.2M | $19.6M | ||
| Q1 25 | $50.8M | $17.5M | ||
| Q4 24 | $52.0M | $19.1M | ||
| Q3 24 | $58.0M | $20.2M | ||
| Q2 24 | $66.2M | $21.4M | ||
| Q1 24 | $65.1M | $19.3M |
| Q4 25 | $-10.6M | $-4.2M | ||
| Q3 25 | $-8.5M | $-8.2M | ||
| Q2 25 | $-34.2M | $-11.9M | ||
| Q1 25 | $-11.6M | $-14.2M | ||
| Q4 24 | $-707.0K | $-11.8M | ||
| Q3 24 | $2.3M | $-11.1M | ||
| Q2 24 | $3.8M | $-12.3M | ||
| Q1 24 | $-5.0M | $-16.3M |
| Q4 25 | 23.3% | 87.3% | ||
| Q3 25 | 28.0% | 86.4% | ||
| Q2 25 | 28.1% | 84.8% | ||
| Q1 25 | 29.9% | 86.2% | ||
| Q4 24 | 31.0% | 86.8% | ||
| Q3 24 | 32.3% | 83.9% | ||
| Q2 24 | 28.8% | 85.8% | ||
| Q1 24 | 29.3% | 85.5% |
| Q4 25 | -25.7% | -18.0% | ||
| Q3 25 | -18.9% | -39.7% | ||
| Q2 25 | -66.7% | -59.6% | ||
| Q1 25 | -11.9% | -79.2% | ||
| Q4 24 | -0.9% | -62.5% | ||
| Q3 24 | 1.0% | -55.7% | ||
| Q2 24 | 6.6% | -59.2% | ||
| Q1 24 | -5.9% | -76.4% |
| Q4 25 | -26.0% | -20.4% | ||
| Q3 25 | -19.2% | -41.0% | ||
| Q2 25 | -66.7% | -61.0% | ||
| Q1 25 | -22.9% | -80.8% | ||
| Q4 24 | -1.4% | -62.1% | ||
| Q3 24 | 4.0% | -54.9% | ||
| Q2 24 | 5.7% | -57.7% | ||
| Q1 24 | -7.7% | -84.4% |
| Q4 25 | $-0.50 | $-0.07 | ||
| Q3 25 | $-0.41 | $-0.16 | ||
| Q2 25 | $-1.65 | $-0.23 | ||
| Q1 25 | $-0.56 | $-0.28 | ||
| Q4 24 | $-0.03 | $-0.23 | ||
| Q3 24 | $0.11 | $-0.22 | ||
| Q2 24 | $0.18 | $-0.25 | ||
| Q1 24 | $-0.24 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $26.9M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $32.8M | $63.9M |
| Total Assets | $88.0M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.9M | $92.0M | ||
| Q3 25 | $36.1M | $92.4M | ||
| Q2 25 | $41.1M | $101.5M | ||
| Q1 25 | $54.7M | $108.8M | ||
| Q4 24 | $50.1M | $120.4M | ||
| Q3 24 | $52.0M | $118.6M | ||
| Q2 24 | $46.0M | $118.2M | ||
| Q1 24 | $55.3M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $32.8M | $63.9M | ||
| Q3 25 | $43.1M | $64.3M | ||
| Q2 25 | $51.5M | $70.0M | ||
| Q1 25 | $85.1M | $77.6M | ||
| Q4 24 | $96.2M | $87.5M | ||
| Q3 24 | $96.4M | $95.0M | ||
| Q2 24 | $93.5M | $101.6M | ||
| Q1 24 | $96.7M | $109.2M |
| Q4 25 | $88.0M | $115.3M | ||
| Q3 25 | $100.3M | $116.3M | ||
| Q2 25 | $109.8M | $122.0M | ||
| Q1 25 | $148.7M | $129.7M | ||
| Q4 24 | $144.8M | $142.8M | ||
| Q3 24 | $146.0M | $143.6M | ||
| Q2 24 | $152.7M | $149.7M | ||
| Q1 24 | $169.9M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.2M | $-1.8M |
| Free Cash FlowOCF − Capex | $-9.2M | $-2.0M |
| FCF MarginFCF / Revenue | -22.7% | -9.7% |
| Capex IntensityCapex / Revenue | 0.1% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-23.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.2M | $-1.8M | ||
| Q3 25 | $-2.2M | $-8.7M | ||
| Q2 25 | $-12.3M | $-7.5M | ||
| Q1 25 | $7.0M | $-11.6M | ||
| Q4 24 | $-1.2M | $-3.5M | ||
| Q3 24 | $7.4M | $362.0K | ||
| Q2 24 | $-8.5M | $-9.5M | ||
| Q1 24 | $7.1M | $-9.8M |
| Q4 25 | $-9.2M | $-2.0M | ||
| Q3 25 | $-4.8M | $-8.9M | ||
| Q2 25 | $-13.6M | $-7.8M | ||
| Q1 25 | $4.6M | — | ||
| Q4 24 | $-1.9M | $-3.6M | ||
| Q3 24 | $6.1M | $311.0K | ||
| Q2 24 | $-9.2M | $-9.5M | ||
| Q1 24 | $5.9M | $-9.9M |
| Q4 25 | -22.7% | -9.7% | ||
| Q3 25 | -10.8% | -44.7% | ||
| Q2 25 | -26.5% | -39.6% | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | -3.7% | -18.9% | ||
| Q3 24 | 10.6% | 1.5% | ||
| Q2 24 | -13.9% | -44.7% | ||
| Q1 24 | 9.0% | -51.4% |
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 5.9% | 0.9% | ||
| Q2 25 | 2.5% | 1.1% | ||
| Q1 25 | 4.7% | 0.0% | ||
| Q4 24 | 1.5% | 0.7% | ||
| Q3 24 | 2.2% | 0.3% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 1.9% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.18× | — | ||
| Q2 24 | -2.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PETS
| Reorder | $34.0M | 84% |
| New Order | $5.0M | 12% |
| Membership Fees | $1.6M | 4% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
